1 / 6

3-1

3-1. 3-1. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients Antithrombotic Trialists’ Collaboration (N = 212,000 in 287 trials). BMJ 324:71–86, 2002. 3-2. 3-2. Antiplatelet Meta-Analysis.

ezhno
Download Presentation

3-1

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 3-1 3-1

  2. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients • Antithrombotic Trialists’ Collaboration • (N = 212,000 in 287 trials) BMJ 324:71–86, 2002 3-2 3-2

  3. Antiplatelet Meta-Analysis Endpoints: MI, Stroke, Vascular Death ASA Dose (mg) No. of Trials Odds Ratio & 95% CI Anti- platelet Control 500-1500 14.5% 17.2% Odds ¯: 19% 34 160-325 11.5% 14.8% 26% 19 75-150 10.9% 15.2% 32% 12 < 75 17.3% 19.4% 13% 3 Treatment effect p < 0.0001 12.9% 16.0% Any Aspirin 23% 65 0 0.5 1 1.5 2 Antiplatelet Better Antiplatelet Worse Antithrombotic Trialists Collaboration, BMJ 324:71–86, 2002 3-3 3-3

  4. CURE Placebo+ASA Arm Primary Endpoint: MI, stroke or CV death p=0.003; <100mg vs >200mg p=0.001 % of Patients with primary endpoint  100mg 110–162mg  200mg N=4,172 N=5,259 N=3,115 3-4 3-4

  5. CURE Study: Placebo+ASA Arm Major Bleeding (including Life-Threatening) % of Patients with Event  100mg 110–162mg  200mg Source: Cure Study 3-15 3-15

  6. Improved Compliance with Combination Tablet vs. Dual Therapy • Diabetes1: • 21% improvement in tablet consumption over 6 month period in previously treated patients • Hypertension: • 13% improvement in tablet consumption over 12 month period2 • 11% improvement in prescription renewal over 12 month period3 • HIV4: • 9% reduction in missing even one dose over 16 week period • 1 White & Hopson (2002) Clin Ther - in press • 2 White & Hopson (2002) in press • 3 Dezii (2000) Manag. Care4 Eron et al (2000) AIDS Jan-D-8 Jan-D-8

More Related